Reduced expression of TRF1 is associated with tumor progression and poor prognosis in oral squamous cell carcinoma

Chuang,Hui-Ching; Chen,Chang-Han; Huang,Chao-Cheng; Fang,Fu-Min; Tsai,Hsin-Ting; Chien,Chih-Yen

doi:10.3892/etm.2010.168

Reduced expression of TRF1 is associated with tumor progression and poor prognosis in oral squamous cell carcinoma

Authors:
- Hui-Ching Chuang
- Chang-Han Chen
- Chao-Cheng Huang
- Fu-Min Fang
- Hsin-Ting Tsai
- Chih-Yen Chien
View Affiliations

Affiliations: Department of Otolaryngology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung 833, Taiwan, R.O.C., Department of Pathology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung 833, Taiwan, R.O.C., Department of Radiation Oncology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung 833, Taiwan, R.O.C.
Published online on: December 2, 2010 https://doi.org/10.3892/etm.2010.168
Pages: 63-67

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The functions of telomeric repeat-binding factor 1 (TRF1) and 2 (TRF2) in oral carcinogenesis are largely unexplored. This study examined the relationship between the expression of TRF1 and TRF2 and clinicopathological variables and survival in oral cavity squamous cell carcinoma (OCSCC). Western blotting and immunohistochemistry were used to evaluate the protein expression of TRF1 and TRF2 in paired OCSCC patient specimens. Expression of TRF1 and TRF2 was assessed by immunohistochemistry in 256 OCSCC patients who underwent tumor resection without previous radiotherapy. The results were analyzed using Fisher's exact test. Protein expression of TRF1 and TRF2 was significantly lower in the OCSCC than in the adjacent non-tumor tissue. Reduced TRF1 and TRF2 levels in 256 patients, as revealed by immunohistochemistry, were significantly associated with aggressive clinicopathological features, such as advanced tumor stage (p<0.001) and advanced tumor node metastasis stage (p<0.001). According to Kaplan-Meier analysis, reduced TRF1 expression was significantly correlated with an unfavorable cumulative 5-year overall survival rate (p<0.001). In conclusion, decreased expression of TRF1 was significantly associated with tumor progression and poor prognosis in OCSCC patients.

View Figures

View References

1.	Shah JP and Singh B: Why the lack of progress for oral cancer? Lancet Oncol. 7:356–357. 2006. View Article : Google Scholar : PubMed/NCBI
2.	Chien CY, Su CY, Chuang HC, et al: Angiopoietin-1 and -2 expression in recurrent squamous cell carcinoma of the oral cavity. J Surg Oncol. 97:273–277. 2008. View Article : Google Scholar : PubMed/NCBI
3.	Chen PH, Ko YC, Yang YH, et al: Important prognostic factors of long-term oropharyngeal carcinoma survivors in Taiwan. Oral Oncol. 40:847–855. 2004. View Article : Google Scholar : PubMed/NCBI
4.	Matsuo JM, Patel SG, Singh B, et al: Clinical nodal stage is an independently significant predictor of distant failure in patients with squamous cell carcinoma of the larynx. Ann Surg. 238:412–421. 2003.PubMed/NCBI
5.	Chien CY, Su CY, Chuang HC, et al: Comprehensive study on the prognostic role of osteopontin expression in oral squamous cell carcinoma. Oral Oncol. 45:798–802. 2009. View Article : Google Scholar : PubMed/NCBI
6.	Chen CH, Chien CY, Huang CC, et al: Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. Oncogene. 28:2723–2737. 2009. View Article : Google Scholar : PubMed/NCBI
7.	Vaziri H, Schachter F, Uchida I, et al: Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am J Hum Genet. 52:661–667. 1993.PubMed/NCBI
8.	Van Steensel B and de Lange T: Control of telomere length by the human telomeric protein TRF1. Nature. 385:740–743. 1997.
9.	Smogorzewska A, van Steensel B, Bianchi A, et al: Control of human telomere length by TRF1 and TRF2. Mol Cell Biol. 20:1659–1668. 2000. View Article : Google Scholar : PubMed/NCBI
10.	Sfeir A, Kosiyatrakul ST, Hockemeyer D, et al: Mammalian telomeres resemble fragile sites and require TRF1 for efficient replication. Cell. 138:90–103. 2009. View Article : Google Scholar : PubMed/NCBI
11.	Van Steensel B, Smogorzewska A and de Lange T: TRF2 protects human telomeres from end-to-end fusions. Cell. 92:401–413. 1998.PubMed/NCBI
12.	Ancelin K, Brunori M, Bauwens S, et al: Targeting assay to study the cis functions of human telomeric proteins: evidence for inhibition of telomerase by TRF1 and for activation of telomere degradation by TRF2. Mol Cell Biol. 22:3474–3487. 2002. View Article : Google Scholar : PubMed/NCBI
13.	Yamada K, Yagihashi A, Yamada M, et al: Decreased gene expression for telomeric-repeat binding factors and TIN2 in malignant hematopoietic cells. Anticancer Res. 22:1315–1320. 2002.PubMed/NCBI
14.	Yamada M, Tsuji N, Nakamura M, et al: Down-regulation of TRF1, TRF2 and TIN2 genes is important to maintain telomeric DNA for gastric cancers. Anticancer Res. 22:3303–3307. 2002.PubMed/NCBI
15.	Miyachi K, Fujita M, Tanaka N, Sasaki K and Sunagawa M: Correlation between telomerase activity and telomeric-repeat binding factors in gastric cancer. J Exp Clin Cancer Res. 21:269–275. 2002.PubMed/NCBI
16.	Lin X, Gu J, Lu C, Spitz MR and Wu X: Expression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancer. Clin Cancer Res. 12:5720–5725. 2006. View Article : Google Scholar : PubMed/NCBI
17.	Raynaud CM, Jang SJ, Nuciforo P, et al: Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions. Ann Oncol. 19:1875–1881. 2008. View Article : Google Scholar : PubMed/NCBI
18.	Frias C, Garcia-Aranda C, De Juan C, et al: Telomere shortening is associated with poor prognosis and telomerase activity correlates with DNA repair impairment in non-small cell lung cancer. Lung Cancer. 60:416–425. 2008. View Article : Google Scholar : PubMed/NCBI
19.	d’Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al: A DNA damage checkpoint response in telomere-initiated senescence. Nature. 426:194–198. 2003.PubMed/NCBI
20.	Yajima T, Yagihashi A, Kameshima H, Kobayashi D, Hirata K and Watanabe N: Telomerase reverse transcriptase and telomeric-repeat binding factor protein 1 as regulators of telomerase activity in pancreatic cancer cells. Br J Cancer. 85:752–757. 2001. View Article : Google Scholar
21.	Salhab M, Jiang WG, Newbold RF and Mokbel K: The expression of gene transcripts of telomere-associated genes in human breast cancer: correlation with clinico-pathological parameters and clinical outcome. Breast Cancer Res Treat. 109:35–46. 2008. View Article : Google Scholar
22.	Feldser DM, Hackett JA and Greider CW: Telomere dysfunction and the initiation of genome instability. Nat Rev Cancer. 3:623–627. 2003. View Article : Google Scholar : PubMed/NCBI
23.	Chong L, van Steensel B, Broccoli D, et al: A human telomeric protein. Science. 270:1663–1667. 1995. View Article : Google Scholar : PubMed/NCBI
24.	Broccoli D, Smogorzewska A, Chong L and de Lange T: Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2. Nat Genet. 17:231–235. 1997. View Article : Google Scholar : PubMed/NCBI
25.	Saito K, Yagihashi A, Nasu S, Izawa Y, et al: Gene expression for suppressors of telomerase activity (telomeric-repeat binding factors) in breast cancer. Jpn J Cancer Res. 93:253–258. 2002. View Article : Google Scholar : PubMed/NCBI
26.	Yamada K, Yajima T, Yagihashi A, et al: Role of human telomerase reverse transcriptase and telomeric-repeat binding factor proteins 1 and 2 in human hematopoietic cells. Jpn J Cancer Res. 91:1278–1284. 2000. View Article : Google Scholar : PubMed/NCBI
27.	La Torre D, de Divitiis O, Conti A, et al: Expression of telomeric repeat binding factor-1 in astroglial brain tumors. Neurosurgery. 56:802–810. 2005.PubMed/NCBI
28.	Kishi S, Wulf G, Nakamura M and Lu KP: Telomeric protein Pin2/TRF1 induces mitotic entry and apoptosis in cells with short telomeres and is down-regulated in human breast tumors. Oncogene. 20:1497–1508. 2001. View Article : Google Scholar : PubMed/NCBI
29.	Oh BK, Kim YJ, Park C and Park YN: Up-regulation of telomere-binding proteins, TRF1, TRF2, and TIN2 is related to telomere shortening during human multistep hepatocarcinogenesis. Am J Pathol. 166:73–80. 2005. View Article : Google Scholar : PubMed/NCBI
30.	Klapper W, Qian W, Schulte C and Parwaresch R: DNA damage transiently increases TRF2 mRNA expression and telomerase activity. Leukemia. 17:2007–2015. 2003. View Article : Google Scholar : PubMed/NCBI
31.	Klapper W, Krams M, Qian W, Janssen D and Parwaresch R: Telomerase activity in B-cell non-Hodgkin lymphomas is regulated by hTERT transcription and correlated with telomere-binding protein expression but uncoupled from proliferation. Br J Cancer. 89:713–719. 2003. View Article : Google Scholar
32.	Nakanishi K, Kawai T, Kumaki F, et al: Expression of mRNAs for telomeric repeat binding factor (TRF)-1 and TRF2 in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Clin Cancer Res. 9:1105–1111. 2003.PubMed/NCBI